You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Harvard Business School
McKinsey
Moodys
McKesson
Medtronic

Last Updated: April 17, 2021

DrugPatentWatch Database Preview

GLEOLAN Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

When do Gleolan patents expire, and when can generic versions of Gleolan launch?

Gleolan is a drug marketed by Nxdc and is included in one NDA.

The generic ingredient in GLEOLAN is aminolevulinic acid hydrochloride. There are six drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the aminolevulinic acid hydrochloride profile page.

Summary for GLEOLAN
US Patents:0
Applicants:1
NDAs:1
Bulk Api Vendors: 126
Clinical Trials: 1
Patent Applications: 190
Formulation / Manufacturing:see details
What excipients (inactive ingredients) are in GLEOLAN?GLEOLAN excipients list
DailyMed Link:GLEOLAN at DailyMed
Drug patent expirations by year for GLEOLAN
DrugPatentWatch® Estimated Generic Entry Opportunity Date for GLEOLAN
Generic Entry Date for GLEOLAN*:
Constraining patent/regulatory exclusivity:
OPTICAL IMAGING AGENT INDICATED IN PATIENTS WITH GLIOMA (SUSPECTED WORLD HEALTH ORGANIZATION GRADES III OR IV ON PREOPERATIVE IMAGING) AS AN ADJUNCT FOR THE VISUALIZATION OF MALIGNANT TISSUE DURING SURGERY
NDA:
Dosage:
FOR SOLUTION;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for GLEOLAN

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
NX Development CorpPhase 3

See all GLEOLAN clinical trials

US Patents and Regulatory Information for GLEOLAN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Nxdc GLEOLAN aminolevulinic acid hydrochloride FOR SOLUTION;ORAL 208630-001 Jun 6, 2017 RX Yes Yes   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Baxter
Johnson and Johnson
Medtronic
Dow
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.